Brokerages Anticipate Mirati Therapeutics Inc (MRTX) to Announce -$1.22 EPS

Share on StockTwits

Equities research analysts predict that Mirati Therapeutics Inc (NASDAQ:MRTX) will post earnings of ($1.22) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Mirati Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.30) and the highest estimate coming in at ($1.17). Mirati Therapeutics posted earnings per share of ($0.94) in the same quarter last year, which would suggest a negative year over year growth rate of 29.8%. The company is scheduled to announce its next earnings results on Wednesday, August 7th.

On average, analysts expect that Mirati Therapeutics will report full year earnings of ($5.00) per share for the current financial year, with EPS estimates ranging from ($5.35) to ($4.74). For the next year, analysts expect that the company will post earnings of ($5.42) per share, with EPS estimates ranging from ($6.70) to ($4.29). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Mirati Therapeutics.

Mirati Therapeutics (NASDAQ:MRTX) last released its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.20). The firm had revenue of $1.24 million during the quarter.

Several research analysts have recently issued reports on MRTX shares. BidaskClub raised Mirati Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. HC Wainwright reaffirmed a “buy” rating on shares of Mirati Therapeutics in a research note on Friday, February 15th. Oppenheimer set a $81.00 price target on Mirati Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 7th. Piper Jaffray Companies started coverage on Mirati Therapeutics in a research note on Friday, February 15th. They set an “overweight” rating and a $85.00 price target for the company. Finally, Cantor Fitzgerald started coverage on Mirati Therapeutics in a research note on Monday, March 4th. They set a “neutral” rating and a $66.00 price target for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Mirati Therapeutics has an average rating of “Buy” and a consensus price target of $69.08.

Shares of NASDAQ:MRTX traded up $2.25 during midday trading on Friday, hitting $76.74. 403,061 shares of the stock were exchanged, compared to its average volume of 674,235. The company has a market capitalization of $2.77 billion, a PE ratio of -24.06 and a beta of 1.95. Mirati Therapeutics has a twelve month low of $28.50 and a twelve month high of $80.00.

In related news, CEO Charles M. Baum sold 51,810 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $75.67, for a total value of $3,920,462.70. Following the completion of the transaction, the chief executive officer now owns 117,851 shares of the company’s stock, valued at approximately $8,917,785.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael G. Grey sold 5,760 shares of Mirati Therapeutics stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $65.30, for a total value of $376,128.00. Following the completion of the sale, the director now owns 7,100 shares of the company’s stock, valued at approximately $463,630. The disclosure for this sale can be found here. Insiders sold a total of 641,851 shares of company stock valued at $45,709,698 in the last three months. 4.86% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC purchased a new stake in Mirati Therapeutics in the 1st quarter valued at about $40,000. Meeder Asset Management Inc. grew its holdings in Mirati Therapeutics by 12.9% in the 4th quarter. Meeder Asset Management Inc. now owns 2,087 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 239 shares during the period. Legal & General Group Plc grew its holdings in Mirati Therapeutics by 16.5% in the 4th quarter. Legal & General Group Plc now owns 3,635 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 515 shares during the period. Great West Life Assurance Co. Can grew its holdings in Mirati Therapeutics by 58.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,130 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 1,149 shares during the period. Finally, Creative Planning purchased a new stake in Mirati Therapeutics in the 1st quarter valued at about $231,000.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

See Also: Risk Tolerance

Get a free copy of the Zacks research report on Mirati Therapeutics (MRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report